Risk-reducing salpingo-oophorectomy (RRSO) is the most definitive surgical intervention for ovarian cancer risk reduction among BRCA1/2 mutation carriers. For women who have completed child-bearing but who are not ready for RRSO, bilateral salpingectomy with ovarian retention (BSOR) might serve as a temporary measure while definitive risk-reducing surgery is being contemplated. Here we summarize recent insights into the pathogenesis of hereditary ovarian cancer which might provide a basis for considering the proposed BSOR management strategy and outline the evidence for and against this potential risk-reducing intervention. Based on the evidence presented, we suggest that there may be sufficient merit in this proposed intervention to consid...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Without preventive interventions, women with germline pathogenic variants in BRCA1 or BRCA2 have hig...
Bilateral salpingo-oophorectomy (BSO) has become the standard-of-care for risk reduction in women at...
Bilateral salpingo-oophorectomy (BSO) has become the standard-of-care for risk reduction in women at...
Background: The availability of genetic testing for inherited mutations in the BRCA1 gene provides p...
Inherited mutations in BRCA1 and BRCA2 increase sigfincantly the risk of developing breast and ovari...
Introduction Women who carry BRCA1/2 mutations have an increased risk for breast and ovarian cancer....
OBJECTIVE: To identify influencing factors of BRCA1/2 mutation carriers and their professionals for ...
Women who have inherited mutations in the BRCA1 or BRCA2 ( BRCA1/2) genes have substantially elevate...
Risk-reducing bilateral salpingo-oophorectomy is a proven strategy to reduce the risk of serous ovar...
Women who have inherited mutations in the BRCA1 or BRCA2 ( BRCA1/2) genes have substantially elevate...
OBJECTIVE: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
IntroductionPreventive bilateral salpingo-oophorectomy is the most effective means of reducing the r...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Without preventive interventions, women with germline pathogenic variants in BRCA1 or BRCA2 have hig...
Bilateral salpingo-oophorectomy (BSO) has become the standard-of-care for risk reduction in women at...
Bilateral salpingo-oophorectomy (BSO) has become the standard-of-care for risk reduction in women at...
Background: The availability of genetic testing for inherited mutations in the BRCA1 gene provides p...
Inherited mutations in BRCA1 and BRCA2 increase sigfincantly the risk of developing breast and ovari...
Introduction Women who carry BRCA1/2 mutations have an increased risk for breast and ovarian cancer....
OBJECTIVE: To identify influencing factors of BRCA1/2 mutation carriers and their professionals for ...
Women who have inherited mutations in the BRCA1 or BRCA2 ( BRCA1/2) genes have substantially elevate...
Risk-reducing bilateral salpingo-oophorectomy is a proven strategy to reduce the risk of serous ovar...
Women who have inherited mutations in the BRCA1 or BRCA2 ( BRCA1/2) genes have substantially elevate...
OBJECTIVE: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
IntroductionPreventive bilateral salpingo-oophorectomy is the most effective means of reducing the r...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...
Objective: Women with a BRCA1/2 mutation or members of a hereditary breast ovarian cancer family (HB...